Refine by MP, party, committee, province, or result type.

Results 1-15 of 52
Sorted by relevance | Sort by date: newest first / oldest first

Health committee  I'll respond to something you said. I think the practical solution to the 23,000 drugs problem is one that I encountered when I was practising in Detroit, at the cancer centre there. The pharmacist was in the clinic with us, and he or she had access to the electronic database. A

March 11th, 2008Committee meeting

Dr. William Hryniuk

Health committee  The problem, however, in that situation comes when the funding agency—in this case, the provincial government—won't even fund the drug from the beginning for anybody. What has been proposed—

March 11th, 2008Committee meeting

Dr. William Hryniuk

Health committee  There is at least one example that I'm aware of where the company has come to an agreement with the funding agency that if the drug doesn't work in the first few cycles, no charge will be forwarded by the company to the agency. If the drug does work, then the agency will pay for

March 11th, 2008Committee meeting

Dr. William Hryniuk

Health committee  In cancer medicine, the disease we're treating is so serious and the drugs themselves have enough side effects that we know of that the patients are willing to put up with this. So the issue of adverse effects in oncology drugs is not the pressing problem that it might be with mo

March 11th, 2008Committee meeting

Dr. William Hryniuk

March 11th, 2008Committee meeting

Dr. William Hryniuk

Health committee  The Cancer Advocacy Coalition is struggling with just that question of transparency and accountability to the public for just exactly the reasons you have outlined. The mechanism that seems to be working—at least it's evolving, for example, for the joint oncology drug review mec

March 11th, 2008Committee meeting

Dr. William Hryniuk

Health committee  There will always be some issues that the drug companies won't want to disclose. We would hope to keep those to an absolute minimum, because that secrecy element has impeded, in our opinion, the transparency issue. The website issue is always going to be, who's going to put it on

March 11th, 2008Committee meeting

Dr. William Hryniuk

Health committee  If you have a question on anything in the world, you Google it and you usually find the answer. I don't see the reason why we couldn't have the same kind of mechanism to address the issues you've raised here from Health Canada, for example. We've looked at the Health Canada web

March 11th, 2008Committee meeting

Dr. William Hryniuk

Health committee  Yes. As a matter of fact, there exists an example of a drug that was given to improve the hemoglobin level so that the anemia from the chemotherapy drugs is alleviated without the need for transfusions, only to find that the drug that improves the blood also makes the cancer grow

March 11th, 2008Committee meeting

Dr. William Hryniuk

Health committee  I don't think the strategy is concerned with that, because of its mandate. But to answer your question, the specific program we're talking about isn't being done, but it could easily be done. All the western provinces now have electronic data systems, which could easily be inte

March 11th, 2008Committee meeting

Dr. William Hryniuk

Health committee  I think it comes in two packages, known and unknown. We've historically thought of adverse events as something down the road that was unexpected in chronic use and wasn't predicted from the initial studies. That's one category. The major category, as far as the physician is conc

March 11th, 2008Committee meeting

Dr. William Hryniuk

Health committee  I could bring it down to a very practical approach, to answer the previous questioner. It's never the cost; it's whether you want to do it and how much you want to do. If you had a pilot study of expensive cancer drugs for two years, sampling major cancer centres' use of those

March 11th, 2008Committee meeting

Dr. William Hryniuk

Health committee  However, if I can just add to that, the history of the indications for these drugs is such that you get it into the marketplace, you find that it works for the initial indication, but you soon find with off-label use that it has many other, completely unexpected ramifications. So

March 11th, 2008Committee meeting

Dr. William Hryniuk

Health committee  I'd just like to address one point you made. The Cancer Advocacy Coalition of Canada gets unrestricted grants from the pharmaceutical companies. We provide them with a list of things that we're going to do, and they either do or don't support them. As you can see from this year

March 11th, 2008Committee meeting

Dr. William Hryniuk

Health committee  The additional consideration is that there's some reticence to publish the use of drugs off label, so in fact the communication between professionals about off-label use and effectiveness is inhibited. But if this mechanism were introduced, that would automatically overcome that

March 11th, 2008Committee meeting

Dr. William Hryniuk